Hence, anti-HER2 therapy, which is already in clinical routine for breast cancer patients, clearly demonstrated the power of molecular analysis and targeting of CTCs in the control of metastatic disease and is very encouraging. This evidence concerns the gene ERBB2 and breast cancer.